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Abstract
Background: The pathogenesis of non-allergic rhinitis (NAR) is still largely unknown. Furthermore, it is unclear
whether there is a correlation between the effect of nasal glucocorticoids on nasal inflammation and on nasal
symptoms and quality of life.
Methods: In this pilot study we recruited 12 healthy subjects and 24 patients with recently diagnosed persistent
NAR [12 untreated and 12 under regular treatment with nasal fluticasone furoate (two sprays of 27.5 μg each in
each nostril once daily, total daily dose = 110 μg) for at least 20 days]. Each subject filled a mini rhinoconjunctivitis
quality of life questionnaire (mini RQLQ). Nasal scrapings were obtained from each subject and used to prepare
slides for Diff-Quik and immunocytochemical staining for inflammatory and epithelial cells count, MUC5AC
expression and the general pro-inflammatory transcription factor nuclear factor kB (NF-kB) activation.
Results: The nasal score of the mini RQLQ, the number of nasal inflammatory cells (neutrophils, eosinophils) and
the number of goblet cells are significantly higher in untreated patients with persistent NAR compared with
control subjects and treated NAR patients. The percentage of MUC5AC+ nasal epithelial cells is significantly
increased in untreated patients with persistent NAR compared with the control subjects (41.8 ± 6.4 vs 22.3 ± 4.8,
respectively; p = 0.0403) without significant differences between control subjects and patients with persistent NAR
on regular fluticasone furoate treatment (33.9 ± 5.0 %; p = 0.0604) nor between the 2 groups of persistent NAR
subjects (p = 0.3260). The number of cytosolic and/or nuclear p65+ nasal epithelial and inflammatory cells was
not significantly different between the three groups.
Conclusions: Patients with persistent untreated NAR, compared with normal control subjects and patients with
persistent NAR under regular treatment with nasal fluticasone furoate by at least 20 days, have more nasal
symptoms, worst quality of life and an increased number of nasal inflammatory cells (neutrophils, eosinophils),
goblet cells and MUC5AC+ nasal epithelial cells. This nasal inflammation seems unrelated to NF-kB activation.
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Background
Non-allergic rhinitis (NAR) is a term that can be applied
to any disease of the nose presenting with obstructive and
secretory symptoms, with or without hyperirritability, that
does not have a known allergic [immunoglobulin (Ig)E-
mediated)] etiology. In fact, the disease is “non-allergic”
when allergy has not been proven by proper allergy
examination (history, skin prick testing, measurement of
serum specific IgE antibodies) [1]. This definition can be
narrowed by allowing only chronic conditions to be
included and, therefore, by excluding acute viral and acute
bacterial infections [1]. The pathogenesis of persistent
(chronic) NAR is still largely unknown [2].
Nasal cytology, obtained using nasal scraping, is a
promising, scarcely invasive, tool to investigate nasal
inflammation, but most of the studies have been
performed so far in patients with allergic rhinitis only
[3]. The aim of this study was to investigate, using nasal
cytology, inflammatory cell counts, the activation of the
general pro-inflammatory transcription factor nuclear
factor kB (NF-kB) and the expression of MUC5AC (the
main secretory mucin expressed on the surface of the
nasal epithelium), in patients with untreated persistent
NAR and a control group of normal subjects and to
investigate the response to the regular treatment with
endonasal glucocorticoids, the gold standard treatment,
in a separate cohort of patients with persistent NAR
under regular treatment with nasal glucocorticoids by at
least 20 days. We also have correlated these results with
the quality of life of the subjects using a validated
questionnaire.
Methods
The study was approved by the local ethics committee of
the University Hospital of Ferrara, Italy (www.ospfe.it), and
informed consent was obtained from each participant in
accordance with the principles outlined in the Declaration
of Helsinki.
We recruited 3 groups of subjects, aged between 18 and
65, all lifelong non-smokers, nonatopic [negative skin prick
tests and/or RAST for the most common aeroallergens in
Italy (house-dust mites (Dermatophagoides pteronyssinus
and farinae), cat and dog dander, plant pollens (grass mix,
Parietaria, Olea europaea, Cupressus sempervirens, Betula
pendula, Corylus avellana, Artemisia vulgaris) and molds
(Alternaria tenuis, Aspergillus fumigatus and Cladosporium
herbarum)] and non-asthmatic. Their demographic charac-
teristics are summarised in Table 1. There is a significant
difference in the mean age between the healthy control
group and the patients with NAR+ nasal fluticasone
furoate (FF) (32.5 ± 2.7 vs 48.1 ± 4.0, respectively; 95 %
confidence interval 26.6─38.4 vs 39.2─56.9, respectively;
Mann–Whitney U test p = 0.0091).
The healthy subjects in the control group (n = 12,
mean age 32.5 ± 2.7; 4 M/8 F) were all non-rhinitics and
free from any other nasal disease. A group (n = 12) of
patients were recruited with persistent untreated non-
allergic rhinitis (mean age 39.5 ± 3.7; 4 M/8 F). None of
these patients or control subjects had been treated in
the least 60 days with systemic and/or nasal glucocorti-
coids, anti-histamine 1 receptor drugs, anti-leukotrienes,
methylxanthines, or any kind of immunosuppressing
drugs, mucolytics/antioxidants drugs by systemic or
local routes.
A separate second cohort (n = 12) of patients with
chronic non-allergic rhinitis (mean age 48.1 ± 4.0; 5 M/
7 F) were treated regularly for at least 20 days with nasal
fluticasone furoate (two sprays of 27.5 μg each, in each
nostril once daily, total daily dose = 110 μg) but not anti-
histamine 1 receptor drugs and/or anti-leukotrienes,
methylxanthines, or any kind of other immunosuppres-
sing drugs, mucolytics/antioxidants drugs by systemic or
local routes. All NAR patients in both groups were ini-
tially diagnosed within 12 months of their recruitment
to the study.
Both groups of patients with persistent non-allergic
rhinitis have been previously investigated with nasal en-
doscopy and maxillofacial computed tomography to ex-
clude the presence of rhinosinusal polyposis and all
these patients have never been previously treated with
nasal or sinus surgery.
Each subject recruited to the study completed the
mini rhinoconjunctivitis quality of life questionnaire
(mini RQLQ) [4] (the permission to use the Italian
validated version of this questionnaire was kindly
given to GC by Prof. Elizabeth Juniper; https://
www.qoltech.co.uk/mini_rqlq.html) (Table 2 in supple-
mentary material).
Nasal scrapings and nasal cytology
Each subject recruited to the study underwent a single
nasal scraping. The nasal scraping was performed under
direct visual inspection using a plastic curette in the
middle third of the inferior turbinate, an area previously
reported to have an optimal ratio between ciliated and
mucous-secreting cells, usually in favour of ciliated cells
[5]. There is no single published standardized protocol
for processing these samples and for this reason we have
followed the guidelines for sputum processing.
Table 1 Study subjects demographic characteristics
n Age Sex Mini-RQLQ
score
Healthy control group 12 32.5 ± 2.7 4 M/8 F 8.1 ± 4.4
Nonallergic persistent rhinitis 12 39.5 ± 3.7 4 M/8 F 32.9 ± 5.6
Nonallergic persistent rhinitis
+ nasal FF
12 48.1 ± 4.0 5 M/7 F 15.7 ± 4.7
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Table 2 Italian validated version of the Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ)
Nessun
fastidio
Quasi nessun
fastidio
Un leggero
fastidio
Poco
fastidio
Abbastanza
fastidio
Molto
fastidio
Moltissimo
fastidio
Attività
l. Attività regolari a casa e al lavoro 0 1 2 3 4 5 6
(il lavoro o le faccende che deve
svolgere regolarmente in casa)
2. Attività sociali 0 1 2 3 4 5 6
(es., attività con la famiglia e gli amici,
giocare con i bambini e gli animali
domestici, rapporti sessuali, passatempi)
3. Attività all'aperto 0 1 2 3 4 5 6
(es., giardinaggio, tagliare il prato, stare
seduti all'aperto, praticare sport, fare
una passeggiata)
Sonno
4. Difficoltà a prendere sonno 0 1 2 3 4 5 6
5. Svegliarsi durante la notte 0 1 2 3 4 5 6
6. Mancanza di una buona dormita 0 1 2 3 4 5 6
Problemi generali
7. Affaticamento (mancanza di energia) 0 1 2 3 4 5 6
8. Sete 0 1 2 3 4 5 6
9. Produttività ridotta 0 1 2 3 4 5 6
10. Sentirsi assonnato/a 0 1 2 3 4 5 6
11. Scarsa concentrazione 0 1 2 3 4 5 6
12. Mal di testa 0 1 2 3 4 5 6
13. Sfinimento, spossatezza 0 1 2 3 4 5 6
Problemi pratici
14. La scomodità di dover portare con sé 0 1 2 3 4 5 6
fazzoletti o fazzolettini di carta
15. Il bisogno di strofinarsi il naso o gli occhi 0 1 2 3 4 5 6
16. Il bisogno di soffiarsi ripetutamente il naso 0 1 2 3 4 5 6
Disturbi nasali
17. Naso chiuso 0 1 2 3 4 5 6
18. Naso che cola 0 1 2 3 4 5 6
19. Starnuti 0 1 2 3 4 5 6
20. Catarro in gola 0 1 2 3 4 5 6
Disturbi agli occhi
21. Prurito agli occhi 0 1 2 3 4 5 6
22. Occhi che lacrimano 0 1 2 3 4 5 6
23. Occhi irritati 0 1 2 3 4 5 6
24. Occhi gonfi 0 1 2 3 4 5 6
Aspetti emotivi
25. Si è sentito/a contrariato/a e deluso/a 0 1 2 3 4 5 6
26. Impazienza e inquietudine 0 1 2 3 4 5 6
27. Irritabilità 0 1 2 3 4 5 6
28. Imbarazzo a causa dei disturbi 0 1 2 3 4 5 6
Juniper et al. [4]. The permission to use this Italian validated version of the questionnaire has been kindly allowed to Prof. Gaetano Caramori by Prof. Elizabeth
Juniper; https://www.qoltech.co.uk/mini_rqlq.html
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Nasal scrapes were immediately put onto ice and
maintained at 4° C throughout their processing. Each
nasal scraping was processed by cytocentrifugation, to
obtain at least 4 cytospins from each subject. Cytospin
slides were prepared and dried for 30 min. An average of
at least six slides were prepared from each patient. Two
of these cytospins were stained using Diff-Quik method
exactly according to the Manufacturer’s instructions
(Dade Behring, Milan Italy) for total and differential cell
counts. The remaining slides were wrapped in aluminum
foil and stored at −20 °C before immunocytochemical
staining for MUC5AC and p65.
Immunocytochemistry for MUC5AC and p65 in nasal
cytospins
We used a protocol previously described [6]. Nasal
cytospins were fixed with 4 % paraformaldehyde (PFA,
10 min, 22 °C), washed (PBS 1X, twice for 5 min, 22 °C),
and cells permeabilized (acetone/methanol, 10 min,
−20 °C). The cell endogenous peroxidase activity was
quenched (3 % hydrogen peroxide, 30 min, 22 °C). Non-
specific binding was blocked (5 % normal horse serum
or 5 % normal goat serum, 20 min, 22 °C) before incuba-
tion with the specific mouse anti-MUC5AC clone 45 M1
(sc-21701, Santa Cruz Biotechnology, USA; 1:1100 dilu-
tion, 1 h, 22 °C) or rabbit anti-p65 (sc-372, Santa Cruz
Biotechnology, USA; 1:100 dilution, 1 h, 22 °C). The
selectivity of both these primary antibodies has been
previously described [6, 7]. We did not performed the
immunocytochemical staining for MUC5B because in a
separate pilot study we did not observe any MUC5B+
staining in nasal epithelial cells from either normal sub-
jects or patients with persistent untreated or treated
NAR using appropriate positive controls and a validated
primary antibody [8].
Both MUC5AC and p65 were detected using peroxidase
(Vectastain Elite ABC-Peroxidase Kit Standard, Vector
Laboratories, Burlingame, CA, USA) and DAB substrate
according to the Manufacturer's instructions. Negative
control slides (nonspecific immunoglobulin of the same
isotype of the primary antibody) were included in each
staining run for each patient for every group of subjects
(control subjects, untreated and treated patients with
persistent NAR).
Cell count
Cell counts were performed on the Diff-Quik-stained
slides using an optical microscope at a x1000 total
magnification, by two independent blinded observers
(PC and VI). The mean intra-observer coefficients of
variance with counting were less than 10 %. To have a
more complete data set we counted all cells within spe-
cific grids on each slide (total number of cells), distin-
guishing and counting inflammatory and nasal epithelial
cells, the different subsets of inflammatory cells and the
number of goblet cells among the nasal epithelial cells.
Goblet cells were defined as glandular, modified simple
columnar epithelial cells [9].
The total cell count was standardized for the sample
size (ml) as previously described [6].
All MUC5AC+ and p65+ cells staining brown, indicat-
ing MUC5AC or p65 immunoreactivity, were counted
on each slide. p65+ cells were also quantified for cyto-
plasmic and/or nuclear (an index of activation) staining.
Statistical analysis
Group data were expressed as mean and standard error
(SEM). The Kruskal-Wallis test for nonparametric data
followed by Mann–Whitney U test was used to deter-
mine differences between the three groups of subjects
and the post-test Dunn’s comparison. A probability value
of <0.05 was considered significant.
Results
Clinical parameters
The total mini RQLQ score was significantly increased
in the patients with untreated persistent NAR compared
both to the control normal subjects and the patients
with persistent NAR under regular treatment with FF
(32.9 ± 5.6 vs 8.1 ± 4.4 vs 15.7 ± 4.7, respectively; 95 %
confidence interval 20.6─45.3 vs −1.7─17.8 vs
5.4─26.0, respectively; Mann–Whitney U test p = 0.0011
and p = 0.0224, respectively; one-way ANOVA Dunn’s
multiple comparison test NAR vs NAR + FF p > 0.05),
without significant differences between control subjects
and patients with persistent NAR under regular treat-
ment with nasal FF (Mann–Whitney U test p = 0.0878)
(Kruskal-Wallis test p = 0.0017) (Fig. 1a).
The nasal symptoms (sneezing, stuffy blocked nose,
runny nose) score was significantly increased in the pa-
tients with untreated persistent NAR compared both to
the control normal subjects and the patients with persist-
ent NAR under regular treatment with nasal FF (9.0 ± 1.7
vs 2.0 ± 1.1 vs 4.3 ± 1.2, respectively; 95 % confidence
interval 5.2─12.8 vs −0.3─4.3 vs 1.7─7.0, respectively;
Mann–Whitney U test p = 0.0015 and p = 0.0367, respect-
ively; one-way ANOVA Dunn’s multiple comparison test
NAR vs NAR + FF p > 0.05), without significant differences
between control subjects and patients with persistent
NAR under regular treatment with nasal glucocorticoids
(Mann–Whitney U test p = 0.1280) (Kruskal-Wallis test
p = 0.0032) (Fig. 1b). Furthermore, all patients with per-
sistent NAR (both untreated and treated) showed a sta-
tistically significant worse daily activity score compared
to the control group of normal subjects (6.9 ± 1.5 vs
4.1 ± 1.2 vs 1.4 ± 0.8, respectively; 95 % confidence
interval 3.6─10.3 vs 1.5─6.7 vs −0.4─3.2, respectively;
Mann–Whitney U test p = 0.0022 and p = 0.0357,
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respectively; one-way ANOVA Dunn’s multiple compari-
son test control group vs NAR + FF p > 0.05) (Fig. 1c)
although this score, considered as “the interference of
rhinitis pathology with the daily activities”, was not
significantly affected by topical FF therapy and was
not different between the 2 groups of persistent NAR
subjects (Mann–Whitney U test p = 0.1814) (Kruskal-
Wallis test p = 0.0055).
Total and differential nasal inflammatory cells count
The total number of nasal inflammatory cells count
(Fig. 2a) was significantly increased in patients with un-
treated persistent NAR compared both to the control
normal subjects and patients with persistent NAR
treated with nasal FF (43.5 ± 18.6 vs 0.0 ± 0.0 vs 19.3 ±
14.6, respectively; 95 % confidence interval 2.6─84.4 vs
0.0─0.0 vs −13.0─51.5, respectively; Mann–Whitney U
test p = 0.0001 and p = 0.0165, respectively; two-way
ANOVA Bonferroni multiple comparison column factor
p = 0.1040). There were no significant differences be-
tween control subjects and NAR patients on nasal FF
(Mann–Whitney U test p = 0.0788) (Kruskal-Wallis test
p = 0.0002) (Fig. 2b).
The percentage of nasal neutrophils was significantly
increased in patients with untreated persistent NAR
compared both to the control normal subjects and NAR
patients on nasal FF (65.3 ± 12.5 vs 0.0 ± 0.0 vs 16.7 ±
11.2 %, respectively; 95 % confidence interval 37.8─92.9
vs −0.0─0.0 vs −8.1─41.4, respectively; Mann–Whitney
U test p = 0.0001 and p = 0.0098, respectively) (Kruskal-
Wallis test p = 0.0001) (Fig. 3a).
The percentage of nasal eosinophils was also signifi-
cantly increased in the patients with untreated persist-
ent NAR compared to the control normal subjects
(18.0 ± 9.2 vs 0.0 ± 0.0 %, respectively; 95 % confidence
interval −2.3─38.3 vs −0.0─0.0, respectively; Mann–
Whitney U test p = 0.0071; two-way ANOVA Bonfer-
roni multiple comparison column factor p = 0.2569)
Fig. 1 a) The mini RQLQ total score is significantly increased in the persistent untreated nonallergic rhinitis (NAR) patients compared both to
control normal subjects (NS) and the persistent NAR patients under regular treatment with nasal glucocorticoids (NAR + GC), without any
significant difference between control subjects and persistent NAR patients under regular treatment with nasal glucocorticoids. b) The nasal
symptoms score of the mini RQLQ is significantly increased in the persistent untreated NAR patients compared both to NS and NAR + GC,
without any significant difference between control subjects and persistent NAR patients under regular treatment with nasal glucocorticoids. c)
The interference of rhinitis pathology with the daily activities score of the mini RQLQ is significantly increased both in the persistent untreated
NAR patients and NAR + GC compared with NS, without any significant difference between both groups of persistent NAR patients
Fig. 2 a) Diff-Quik staining of a nasal cytospin showing nasal ciliated epithelial cells (arrow) and nasal inflammatory cells (eosinophils and neutrophils)
stained with Diff-Quik. The nuclei and cytosol of the epithelial cells and neutrophils are stained in purple/blue, cytosol of eosinophil granules is stained
in red (broken arrow). Original magnification: x400. b) The total number of nasal inflammatory cells is significantly increased in the persistent untreated
nonallergic rhinitis (NAR) patients compared both to control normal subjects (NS) and the persistent NAR patients under regular treatment with nasal
glucocorticoids (NAR + GC), without any significant difference between control subjects and persistent NAR patients under regular treatment with
nasal glucocorticoids
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without significant differences between control subjects
and patients with persistent NAR under regular treat-
ment with nasal FF (8.3 ± 8.3 %; 95 % confidence inter-
val −10.0─26.7; Mann–Whitney U test p = 0.3593) nor
between the 2 groups of persistent NAR subjects
(Mann–Whitney U test p = 0.0568) (Kruskal-Wallis test
p = 0.0078) (Fig. 3b).
Total nasal epithelial cells and nasal goblet cells count
The total number of nasal epithelial cells count was sig-
nificantly different between patients with persistent
untreated NAR compared both to the control normal
subjects and NAR patients treated with nasal FF (92.3 ±
17.2 vs 413.8 ± 62.8 vs 407.8 ± 62.6, respectively; 95 %
confidence interval 54.4─130.2 vs 275.7─551.9 vs
270.0─545.7, respectively; Mann–Whitney U test p <
0.0001 and p = 0.0009, respectively) with no significant
differences between control subjects and nasal FF-
treated NAR patients (Mann–Whitney U test p = 0.8852)
(Kruskal-Wallis test p = 0.0001) (Fig. 3c).
The percentage of nasal goblet cells was significantly en-
hanced in untreated NAR patients compared to either
control normal subjects and NAR patients treated with
nasal FF(22.6 ± 5.0 vs 4.4 ± 0.6 vs 3.0 ± 0.4 %, respectively;
95 % confidence interval 11.7─33.5 vs 3.2─5.6 vs
2.1─3.9, respectively; Mann–Whitney U test p = 0.0003
and p = 0.0001, respectively). No significant differences
between control subjects and nasal FF-treated NAR
patients was observed (Mann–Whitney U test p = 0.0876)
(Kruskal-Wallis test p < 0.0001) (Fig. 3d).
Nasal epithelial cells MUC5AC+ count
The immunoreactivity for MUC5AC in the nasal epithelial
cells was localized to both goblet and non-goblet cells
(Fig. 4a).
The percentage of MUC5AC+ nasal epithelial cells
over the total number of nasal epithelial cells was
significantly increased in untreated NAR patients
compared to control normal subjects (41.8 ± 6.4 vs
22.3 ± 4.8 %, respectively; 95 % confidence interval
27.7─55.8 vs 11.6─32.9, respectively; Mann–Whitney
U test p = 0.0403; one-way ANOVA Dunn’s multiple
comparison test p > 0.05). There were no significant
differences between control subjects and NAR pa-
tients on nasal FF (33.9 ± 5.0 %; 95 % confidence
interval 23.0─44.8; Mann–Whitney U test p = 0.0604)
Fig. 3 a) The percentage of neutrophils on total number of nasal inflammatory cells is significantly increased in the persistent untreated
nonallergic rhinitis (NAR) patients compared both to control normal subjects (NS) and the persistent NAR patients under regular treatment with
nasal glucocorticoids (NAR + GC), without any significant difference between control subjects and persistent NAR patients under regular
treatment with nasal glucocorticoids. b) The percentage of eosinophils on total number of nasal inflammatory cells is significantly increased in
the persistent untreated NAR patients compared both to NS and NAR + GC, without any significant difference between control subjects and
persistent NAR patients under regular treatment with nasal glucocorticoids. c) The total number of nasal epithelial cells is significantly increased
in the persistent untreated NAR patients compared both to NS and NAR + GC, without any significant difference between control subjects and
persistent NAR patients under regular treatment with nasal glucocorticoids. d) The percentage of goblet cells on the total number of nasal
epithelial cells is significantly increased in the persistent untreated NAR patients compared both to NS and NAR + GC, without any significant
difference between control subjects and persistent NAR patients under regular treatment with nasal glucocorticoids
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nor between the 2 groups of persistent NAR subjects
(Mann–Whitney U test p = 0.3260) (Kruskal-Wallis
test p = 0.0521) (Fig. 4b-h).
Nasal epithelial and inflammatory cells p65+ count
p65+ nuclear and cytoplasmic staining was observed in
nasal epithelial cells (Fig. 5a-f ). There was no difference
between any of the groups studied with respect to
cytosolic and/or nuclear p65 staining (Fig. 5g and h). In
detail, the percentage of cytosolic (42.5 ± 3.8 vs 45.2 ±
4.2 vs 41.2 ± 2.5 %, untreated persistent NAR patients vs
control normal subjects vs NAR patients under regular
FF treatment, respectively; 95 % confidence interval
34.2─50.8 vs 35.8─54.5 vs 35.7─46.7, respectively;
Kruskal-Wallis test p = 0.9270) and nuclear (0.03 ± 0.03
vs 0.1 ± 0.09 vs 0.0 ± 0.0 %, untreated persistent NAR
patients vs control normal subjects vs NAR patients under
regular FF treatment, respectively; 95 % confidence inter-
val −0.03─0.08 vs −0.07─0.3 vs 0.0─0.0, respectively;
Kruskal-Wallis test p = 0.3262) p65+ nasal epithelial cells
compared with the total number of nasal epithelial cells
did not differ significantly between the 3 subject groups.
In addition, no difference in these parameters were
observed for the nasal inflammatory cells.
Correlations between inflammatory cells and MUC5AC
expression
There was no significant correlation between the num-
ber and/or type of inflammatory cells and MUC5AC ex-
pression in the nasal epithelial cells. In addition the
outliers in the number of inflammatory cells and in the
MUC5AC expression in the nasal epithelial cells were
not the same patients.
Discussion
We have shown here for the first time that patients with
untreated persistent NAR, compared to control normal
subjects, have an increased number of nasal inflammatory
cells (both neutrophils and/or eosinophils) and nasal gob-
let cells and that the regular treatment with nasal FF for at
Fig. 4 a) Photomicrograph showing a nasal epithelial cell immunostained for identification of MUC5AC+ cells. Nuclei are stained in purple/blue
(arrow), cytoplasmic mucin MUC5AC is stained in brown. b) The percentage of MUC5AC+ nasal epithelial cells over the total number of nasal epithelial
cells is significantly increased in the persistent untreated nonallergic rhinitis (NAR) patients compared both to control normal subjects (NS) and the
persistent NAR patients under regular treatment with nasal glucocorticoids (NAR + GC), without any significant difference between control subjects
and persistent NAR patients under regular treatment with nasal glucocorticoids. The immunocytochemical images in the right panel are representative
of those from 12 control group subjects (c), 12 patients with persistent untreated NAR (d) and 12 patients with persistent NAR under regular treatment
with nasal glucocorticoids (e). The images f, g and h are their representative negative controls (nonspecific mouse IgG). Original magnification: x400.
Bar =50 μm
Fig. 5 a) Photomicrographs showing nasal epithelial cells immunostained for identification of p65+ cells. Nuclei are stained in purple/blue, p65 is
stained in brown. The immunocytochemical images in the left panel are representative of those from 12 control normal subjects (NS) (A), 12
patients with persistent untreated nonallergic rhinitis (NAR) patients (b) and 12 patients with persistent NAR patients under regular treatment
with nasal glucocorticoids (NAR + GC) (c). The images d, e and f are the negative controls (nonspecific rabbit IgG). Original magnification: x400.
Bar = 50 μm. The percentage of cytosolic only p65+ nasal epithelial cells (g) and nuclear p65+ nasal epithelial cells (h) over total nasal epithelial
cells is not significantly different between persistent untreated NAR patients, NS and NAR + GC
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least 20 days, is associated with a significant reduction in
the number of these inflammatory cells as previously ob-
served in controlled clinical trials performed in patients
with chronic allergic rhinitis [10]. In addition we have also
shown for the first time a significant increase in the num-
ber of MUC5AC+ nasal epithelial cells in patients with
untreated persistent NAR, compared with control normal
subjects, whereas their number is not significantly differ-
ent between control subjects and persistent NAR patients
under regular treatment with nasal FF.
The effect of the glucocorticoids on MUC5AC expres-
sion is still quite controversial. In vitro the effects of glu-
cocorticoids on the expression of MUCAC appear cell-
type dependent. For example, fluticasone propionate
significantly reduced MUC5AC protein expression in
the human lung mucoepidermoid carcinoma cell line
(H292 cells) [11], whereas a treatment with dexametha-
sone did not change significantly the steady-state mes-
senger ribonucleic acid (mRNA) levels of MUC5AC in
cultured human nasal epithelial cells obtained from
nasal polyps [12] and even enhanced both MUC5AC
protein secretion and MUC5AC mRNA expression in cul-
tured normal human bronchial epithelial cells [13–15]. In
addition, in an animal model of rhinovirus infection fluti-
casone propionate increased MUC5AC protein level in
the bronchoalveolar lavage [16].
Tang et al. reported a significant decrease in MUC5AC
mRNA in human nasal epithelial cells and of MUC5AC
expression in nasal mucosal biopsy specimens in pa-
tients with allergic rhinitis after treatment with flutica-
sone propionate (100 μg of nasal spray per nostril once
daily for 4 weeks). In this report, patients with traumatic
optic neuropathy ready for optic nerve decompression
were enrolled as controls [17]. In contrast, nasal admin-
istration of glucocorticoids increased the level of mucin
recovered by nasal lavage of non-atopic subjects. In this
study, subjects were randomized to receive either 200 μg
of fluticasone propionate once daily or 100 μg of beclo-
methasone dipropionate twice daily to one nostril and
placebo to the other, chosen randomly [18].
These human data in nasal cells are also in keeping
with other studies performed in the lower airways of
asthmatic patients. For example Groneberg et al. re-
ported no change in MUC5AC protein expression in the
bronchial biopsies after treatment with inhaled budeso-
nide of asthmatic patients [19]. Also Fahy et al. did not
observe any significant effect on mucin-like glycopro-
teins in the sputum of moderate asthmatics by inhaled
beclomethasone dipropionate [20]. The functional role
of MUC5AC in the nasal inflammation is still unknown
but animal data suggests that this secretory mucin is not
involved in the immune defenses of the upper airways
[21] despite its potential protective role during influenza
infection of the lower airways [22].
We did not observe any significant difference in the
nuclear (an index of activation) or cytosolic distribution
and expression of p65, one of the main subunits of NF-
kB, both in the nasal epithelial and inflammatory cells in
all the three groups of subjects. The absence of nuclear
translocation of p65 in all subjects suggests that there
was no spontaneous NF-kB activation during the collec-
tion and processing of the samples. This suggests that
pro-inflammatory gene transcription and MUC5AC
transcription in these groups of subjects are regulated by
other pro-inflammatory transcription factors or path-
ways. The definitive way to determine the role of NF-kB
or of any other transcription factor in driving MUC5AC
expression is to perform chromatin immunoprecipita-
tion (ChIP) analysis in these samples. Samples were not
available for this study and there are concerns that the
sensitivity of the assay would not allow detection in the
small number of cells available from each subject.
Our study has several limitations. Firstly, this was an
open study and the effects of nasal FF must be con-
firmed in a controlled clinical trial using a placebo arm
and a cross-over design. In addition this was a pilot
study examining a small number of patients. We also ac-
knowledge the limitation that the mean age of the group
of patients with persistent NAR under regular treatment
with nasal FF is significantly, albeit slightly, higher com-
pared with the control group of the healthy subjects and
this may have influenced the results.
In addition we did not have any objective confirmation
of patient compliance to nasal FF treatment. However the
presence of reduced nasal symptoms, better quality of life
scores and a decreased number of inflammatory cells ob-
served in nasal scrapings, in the group of patients treated
with nasal FF compared to untreated patients, suggest that
these patients were, at least partially, compliant with this
treatment. In summary our findings suggest the great po-
tential for the use of nasal scrapings in investigating the
molecular pathogenesis of persistent non-allergic rhinitis.
Conclusions
Patients with persistent untreated NAR, compared with
normal control subjects and patients with persistent
NAR under regular treatment with nasal fluticasone
furoate by at least 20 days, have more nasal symptoms,
worst quality of life and an increased number of nasal
inflammatory cells (neutrophils, eosinophils), goblet cells
and MUC5AC+ nasal epithelial cells. This nasal inflam-
mation seems unrelated to NF-kB activation.
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